AU3582995A - Combination immunotoxin/antineoplastic agent therapy for b-lineage cancer - Google Patents

Combination immunotoxin/antineoplastic agent therapy for b-lineage cancer

Info

Publication number
AU3582995A
AU3582995A AU35829/95A AU3582995A AU3582995A AU 3582995 A AU3582995 A AU 3582995A AU 35829/95 A AU35829/95 A AU 35829/95A AU 3582995 A AU3582995 A AU 3582995A AU 3582995 A AU3582995 A AU 3582995A
Authority
AU
Australia
Prior art keywords
immunotoxin
combination
antineoplastic agent
agent therapy
lineage cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU35829/95A
Inventor
Fatih M. Uckun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota System
Original Assignee
University of Minnesota Twin Cities
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota Twin Cities, University of Minnesota System filed Critical University of Minnesota Twin Cities
Publication of AU3582995A publication Critical patent/AU3582995A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU35829/95A 1994-08-22 1995-08-22 Combination immunotoxin/antineoplastic agent therapy for b-lineage cancer Abandoned AU3582995A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US517282 1990-05-01
US29384694A 1994-08-22 1994-08-22
US293846 1994-08-22
US51728295A 1995-08-21 1995-08-21
PCT/US1995/010940 WO1996005865A1 (en) 1994-08-22 1995-08-22 Combination immunotoxin/antineoplastic agent therapy for b-lineage cancer

Publications (1)

Publication Number Publication Date
AU3582995A true AU3582995A (en) 1996-03-14

Family

ID=26968189

Family Applications (1)

Application Number Title Priority Date Filing Date
AU35829/95A Abandoned AU3582995A (en) 1994-08-22 1995-08-22 Combination immunotoxin/antineoplastic agent therapy for b-lineage cancer

Country Status (2)

Country Link
AU (1) AU3582995A (en)
WO (1) WO1996005865A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5965296A (en) * 1995-05-31 1996-12-18 Regents Of The University Of Minnesota Recombinant polypeptide cytotoxins for cancer treatment
US6372217B1 (en) 1997-06-03 2002-04-16 Regents Of The University Of Minnesota Methods for the treatment of CD7+ viral infection with TXU-7-PAP
KR100520182B1 (en) * 1999-09-07 2005-10-10 주식회사 하이닉스반도체 Crosslinker used for silylation and photoresist composition containing the same
US20070178103A1 (en) * 2006-01-30 2007-08-02 Fey Georg H CD19-specific immunotoxin and treatment method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831117A (en) * 1986-01-03 1989-05-16 Uckun Fatih M Monoclonal antibody specific for human B-cells

Also Published As

Publication number Publication date
WO1996005865A1 (en) 1996-02-29

Similar Documents

Publication Publication Date Title
AU1958897A (en) Egf-genistein conjugates for the treatment of cancer
AU2805195A (en) Therapeutic compounds
AU4067697A (en) Therapeutic compositions for treatment of cancer
AU2508597A (en) Drug for the treatment of tumours
AU3532895A (en) Antitumor agent
IL101410A0 (en) Formulation for the treatment of cancer
AU1480497A (en) Cancer treatment
AU2027495A (en) Pharmaceutical composition for treating hemorrhoidal diseases
GB9509572D0 (en) Cancer therapy
AU7166896A (en) Cancer treatment
IL121329A0 (en) A pharmaceutical composition for the treatment of cancer
AU3257095A (en) Deuterium-containing pharmaceutical compositions for destroying tumors
GB9308166D0 (en) Cancer therapy
GB9703633D0 (en) Cancer therapy
HUP0103557A3 (en) Use of an anthracycline derivative for the treatment of a liver tumor
AU7920198A (en) Intratumoral administration of triphenylethylenes for the treatment of cancer
IL106763A0 (en) Pharmaceutical compositions for treating cancer
AU648084B2 (en) Agent for therapy
AU4825993A (en) New compounds for use in the treatment of cancer
AU7130696A (en) Combination of beta-interferon for the treatment of prostate cancer
AU5754996A (en) Agent for the treatment of radiation injuries
AU1014997A (en) A drug for the treatment of cancer
AU2453399A (en) Bone cancer therapy
GB9424578D0 (en) Cancer treatment
AU3030999A (en) Antitumor combination for the treatment of non-small-cell lung cancer